Seven peptides go before the FDA's compounding committee on July 23–24

What PCAC actually is

The Pharmacy Compounding Advisory Committee is an advisory body. It provides independent expert advice to FDA, and its recommendations are non-binding — FDA generally follows them but is not legally required to. This distinction does real work here, because the agency's own scientific staff have already committed to a position in writing, and the committee's job over these two days is to consider whether that position is right.

The meeting runs at FDA's White Oak campus in Silver Spring, Maryland, from 8:00 a.m. on both days, with a live webcast. Public comment sessions are scheduled through each day. The docket for written comment, FDA-2025-N-6895, closes on July 22 — the day before the meeting opens.

What a 503A Bulks List vote changes — and what it doesn't

Section 503A of the Federal Food, Drug, and Cosmetic Act sets the conditions under which a drug compounded by a licensed pharmacist or physician is exempt from three requirements that would otherwise apply: current good manufacturing practice, labelling with adequate directions for use, and new drug approval. One of those conditions concerns the bulk drug substance used. A substance qualifies if it has an applicable USP or National Formulary monograph, or is a component of an FDA-approved drug, or appears on a list FDA develops by regulation — the 503A Bulks List.

None of the seven peptides has a USP or NF monograph. None is a component of an FDA-approved drug. That is precisely why the list is the only available route, and why this meeting exists.

So a favourable vote, followed by rulemaking, would mean: a licensed pharmacist could lawfully use that substance to compound a drug for an individual patient with a valid prescription. It would not mean the compound is safe and effective — that is what approval means, and no approval is on the table here. It would not create a legal consumer product. And it would have no effect at all on research-use-only material, which is governed by an entirely separate set of rules.

The three distinctions that keep getting collapsed

Coverage of this meeting — including a good deal of it written by parties who sell peptides — tends to blur three separate things into one. They are not the same, and the gap between them is where most of the confusion about peptide legality lives.

The seven compounds

Each is being evaluated as two separate substances — the free base and the acetate salt — because FDA treats them as different active ingredients. That is why seven compounds produce fourteen entries on the agenda.

The use column matters more than it looks. FDA evaluates a substance in the context of the use proposed for it — so BPC-157 was assessed for ulcerative colitis, not tendon healing, and MOTS-c for obesity and osteoporosis, not longevity. Several of these compounds are popularly used for indications FDA never reviewed.

Read the briefing on each compound

What FDA staff said, and how uniform it was

Seven documents, running to more than 400 pages, arrive at the same four-part case with remarkable consistency. In every single one:

• Neither form is well characterised. The reasons repeat almost verbatim across the seven: naming conventions that do not follow USAN, INN or IUPAC standards, and missing quality-control data — impurities, aggregates, endotoxins — in both the published literature and the nomination packages, which generally lacked a Certificate of Analysis.
• Immunogenicity risk cannot be assessed. FDA's phrasing is careful and worth reading precisely: it says the information needed to evaluate the risk was not available, so potential risks are unknown. That is not a finding of danger. It is also not a clean bill of health, and it is routinely reported as the latter.
• Approved alternatives already exist for the conditions each was nominated to treat. FDA treats the availability of approved therapy as relevant to the safety criterion.
• The identity problem. Across the seven, FDA repeatedly notes it cannot tell whether the substance in a given published study was the free base or the acetate. That single ambiguity undercuts much of what the literature could otherwise be used to argue.

Where the documents differ is more interesting than where they agree, and the differences are the reason the per-compound pages above exist. Emideltide is the only one FDA credits with genuine historical compounding use — and it is still proposed against. Semax is the only one where FDA says some evidence demonstrated a lack of effectiveness rather than simply failing to establish it. BPC-157 is the only one with adverse-event reports involving compounded product. MOTS-c and KPV have essentially no human data at all.

The withdrawn nominations

Here is a detail that has gone almost entirely unreported, and it changes how the meeting should be read: every one of the seven nominations was withdrawn. FDA is evaluating all fourteen substances at its own discretion, using the information from the withdrawn packages.

That is unusual. The normal shape of this process is that a nominator — often a compounding pharmacy or a trade body — puts a substance forward and defends it. Withdrawal is what removed these peptides from Category 2 in April. FDA then chose to evaluate them anyway. The Federal Register notice still invites nominators to present in support of their nominations, but the packages FDA is working from are ones their sponsors walked away from.

What to watch on the day

Three things will tell you more than the vote tally itself.

Whether the committee splits characterisation from evidence. FDA's characterisation objections are, in principle, fixable — a Certificate of Analysis, endotoxin testing and a USP-style monograph would answer most of them. Its effectiveness objections are not fixable by paperwork. If committee members treat those two buckets differently, that signals a path forward for some substances and a closed door for others.

Whether emideltide is treated differently. It is the one with acknowledged historical compounding use, and the one with the most concrete formulation problem. If the committee splits from staff anywhere, this is a plausible place.

What happens to the acetate/free base pairing. Each compound is two substances. There is no requirement that they be voted together, and the evidence for the two forms is not identical — FDA's inability to tell them apart in the literature cuts both ways.

A second PCAC meeting is expected before the end of February 2027 to review five more peptides: GHK-Cu, melanotan II, cathelicidin (LL-37), dihexa acetate and pegylated mechano growth factor. Whatever reasoning the committee uses in July will shape that meeting too.

A note on the docket number

If you are filing a comment, use FDA-2025-N-6895. There is a discrepancy worth knowing about: FDA's meeting web page gives this number in its public-participation section, but a boilerplate paragraph further down the same page cites a different one, FDA-2026-N-2979. That second number does not appear in the Federal Register notice, which carries FDA-2025-N-6895 in its heading, nor on Regulations.gov, where the docket holding the comments is FDA-2025-N-6895. We have seen the incorrect number reproduced on sites that copied FDA's page verbatim. The docket of record is FDA-2025-N-6895.

Related on Grey Peptides